Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 753 of 5804
-
Immunotherapy before lung surgery shows promise in early trial
Disease control CompletedThe primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.
Phase: PHASE2 • Sponsor: University Hospital, Essen • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Brain games put to the test: can they really stave off dementia?
Disease control Recruiting nowOlder adults at risk for dementia show a variety of cognitive deficits, which can be ameliorated by different cognitive training (CT) exercises. The best combination of CT exercises is unknown. The aim is to discover the most efficacious combination of CT exercises as compared to…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New cocktail of drugs and radiation aims to stop prostate cancer spread
Disease control OngoingThis study is to find out whether adding the study drug atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to treat previously untreated metastatic prostate cancer…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug shows promise for painful skin condition
Disease control CompletedThe purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Lung cancer trial: does adding a second drug boost survival?
Disease control Ongoingphase II controlled randomized study comparing atezolizumab as single agent to the combination of atezolizumab and bevacizumab in patients with chemonaive metastatic NSCLC with PD-L1 expression. All NSCLC patients with tumor tissue available for biomarker assessment and candidate…
Phase: PHASE2 • Sponsor: Fondazione Ricerca Traslazionale • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Triple-Drug cocktail takes on advanced melanoma
Disease control OngoingIn this phase II advanced melanoma study, all patients will receive treatment with nivolumab/ipilimumab plus cabozantinib for a 12 week induction period followed by nivolumab plus cabozantinib maintanence to complete up to 2 years of therapy unless disease progression, dose limit…
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New trial aims to crack code of Drug-Resistant lung bug
Disease control Recruiting nowMycobacterium abscessus (MABS) is a group of rapid-growing, multi-drug resistant non-tuberculous mycobacteria (NTM) causing infections in humans. MABS pulmonary disease (MABS-PD) can result in significant morbidity, increased healthcare utilisation, accelerated lung function decl…
Phase: PHASE2, PHASE3 • Sponsor: The University of Queensland • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Custom-Made DNA vaccine takes on advanced liver cancer
Disease control OngoingThis is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based o…
Phase: PHASE1, PHASE2 • Sponsor: Geneos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could early CMV and TB drugs save HIV-Positive babies with pneumonia?
Disease control CompletedThis trial will evaluate whether empirical treatment against cytomegalovirus and tuberculosis improves survival of HIV-infected infants with severe pneumonia.
Phase: PHASE2, PHASE3 • Sponsor: Hospital Universitario 12 de Octubre • Aim: Disease control
Last updated Jun 26, 2026 18:55 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingA Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer t…
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New pill could fight bladder cancer when standard therapy fails
Disease control CompletedThe purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor fibroblast growth factor receptor (FGFR) mutations or f…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Immunotherapy duo takes on rare sarcoma in new trial
Disease control CompletedThis is a multicenter study assessing the efficacy of nivolumab in association with relatlimab.
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Smart trial takes on MND: could existing drugs slow the disease?
Disease control Recruiting nowMND-SMART is investigating whether selected drugs can slow down the progression of motor neuron disease (MND) and improve survival. The study is 'multi-arm' meaning more than one treatment will be tested at the same time. The trial started with 3 arms; drug 1 (memantine), drug 2…
Phase: PHASE2, PHASE3 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could stem cells help newly diagnosed type 1 diabetes patients?
Disease control OngoingThe goal of this study is to determine the safety and efficacy of fresh metabolically active allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for the treatment of new-onset type 1 diabetes (T1D) and to understand the mechanisms of protection. If proven effect…
Phase: PHASE1 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take aim at Hard-to-Treat brain tumors
Disease control OngoingThis phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive)…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising combo for AML after transplant falls short as trial ends early
Disease control TerminatedThe main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic s…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug duo aims to tackle returning cervical cancer
Disease control OngoingThe purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New targeted therapy shows promise for Hard-to-Treat cancers
Disease control OngoingBrenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp i…
Phase: PHASE1, PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Surgical trick could let amputees 'Feel' their missing limb again
Disease control Recruiting nowThis study will involve the development of a novel approach to lower extremity residual limb surgical revision that offers the promise of augmenting volitional motor control, restore proprioception and reverse atrophy
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New angelman drug shows promise in early safety trial
Disease control CompletedThe primary objective of the study is to evaluate the safety and tolerability of multiple-ascending doses of GTX-102 administered by intrathecal (IT) injection to participants with Angelman Syndrome (AS).
Phase: PHASE1, PHASE2 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC